Reported Standalone quarterly numbers for Shilpa Medicare are: Net Sales at Rs 129.68 crore in September 2024 up 73.8% from Rs. 74.61 crore in September 2023. Quarterly Net Profit at Rs. 30.49 crore in September 2024 up 361.76% from Rs. 6.60 crore in September 2023. EBITDA stands at Rs. 64.33 crore in September 2024 up 114.08% from Rs. 30.05 crore in September 2023.

Shares of Housing & Urban Development Corporation (HUDCO) jumped over 8% on November 25, the most in 7 weeks after BJP-led Mahayuti's alliance sweeping win in Maharashtra state elections brought renewed focus on Centre's capital expenditure (capex) plans. After the government spending stayed flat YoY in first half of this fiscal year, analysts expect the poll result to improve.

Ed Yardeni warns of potential risks ahead due to unusual rally across multiple asset classes, signaling growing euphoria, despite a strong US economy and solid earnings. He cites uncertainties from Trump's policy initiatives and geopolitical tensions, but remains positive on India's economy and long-term prospects.

Reported Standalone quarterly numbers for Fluidomat are: Net Sales at Rs 19.00 crore in September 2024 up 29.67% from Rs. 14.65 crore in September 2023. Quarterly Net Profit at Rs. 6.17 crore in September 2024 up 75.22% from Rs. 3.52 crore in September 2023. EBITDA stands at Rs. 8.44 crore in September 2024 up 72.24% from Rs. 4.90 crore in September 2023.

After weeks of subdued performance, shares of Mindteck (India) hit their 10 percent upper circuit at Rs 272.85, marking a continuation of the previous session's rally. This surge comes after a period of five consecutive losing sessions. Year-to-date, Mindteck shares have gained 43 percent, significantly outperforming the Nifty 50, which has risen 12 percent during the same period.

Reported Standalone quarterly numbers for Everest Organics are: Net Sales at Rs 44.05 crore in September 2024 down 10.92% from Rs. 49.45 crore in September 2023. Quarterly Net Profit at Rs. 0.74 crore in September 2024 up 2400.68% from Rs. 0.03 crore in September 2023. EBITDA stands at Rs. 3.57 crore in September 2024 up 21.02% from Rs. 2.95 crore in September 2023.

Reported Standalone quarterly numbers for Panacea Biotec are: Net Sales at Rs 76.64 crore in September 2024 down 18.98% from Rs. 94.59 crore in September 2023. Quarterly Net Profit at Rs. 1.29 crore in September 2024 down 59.69% from Rs. 3.20 crore in September 2023. EBITDA stands at Rs. 10.15 crore in September 2024 down 16.05% from Rs. 12.09 crore in September 2023.

📌The worst-performing sector in 2024 was FMCG, with a one-year return of 7.5%. 📌The Indian oil & gas sector is vast, and includes a variety of companies. 📌Increased costs of raw materials such as wheat, sugar, edible oil and packaging. 📌The chemical sector was the darling of markets in 2021 and 2022. 📌The cement industry is experiencing a slowdown due to reduced capital expenditure.

Reported Standalone quarterly numbers for Mercury Laboratories are: Net Sales at Rs 18.19 crore in September 2024 down 20.04% from Rs. 22.76 crore in September 2023. Quarterly Net Profit at Rs. 0.50 crore in September 2024 down 66.81% from Rs. 1.51 crore in September 2023. EBITDA stands at Rs. 1.51 crore in September 2024 down 47.02% from Rs. 2.85 crore in September 2023.

Nifty staged a strong comeback this week, surging past the 200-day moving average and trapping bearish sellers. The index found support at its 50-week moving average, forming a bullish hammer pattern. While facing resistance at 24,000, positive sentiment prevails with increased FPI long positions and declining open interest. A sustained move above 24,000 could propel Nifty towards 24,500–24,700.

Reported Standalone quarterly numbers for Ind-Swift are: Net Sales at Rs 136.35 crore in September 2024 up 17.62% from Rs. 115.92 crore in September 2023. Quarterly Net Profit at Rs. 4.11 crore in September 2024 up 138.41% from Rs. 10.71 crore in September 2023. EBITDA stands at Rs. 19.03 crore in September 2024 up 33.17% from Rs. 14.29 crore in September 2023.

Reported Standalone quarterly numbers for Medicamen Biotech are: Net Sales at Rs 42.84 crore in September 2024 up 0.41% from Rs. 42.67 crore in September 2023. Quarterly Net Profit at Rs. 2.27 crore in September 2024 down 24.66% from Rs. 3.01 crore in September 2023. EBITDA stands at Rs. 6.84 crore in September 2024 up 1.94% from Rs. 6.71 crore in September 2023.

Reported Standalone quarterly numbers for Kernex Microsystems (India) are: Net Sales at Rs 41.16 crore in September 2024 up 4893.89% from Rs. 0.82 crore in September 2023. Quarterly Net Profit at Rs. 7.25 crore in September 2024 up 269.99% from Rs. 4.26 crore in September 2023. EBITDA stands at Rs. 10.88 crore in September 2024 up 472.6% from Rs. 2.92 crore in September 2023.

Reported Standalone quarterly numbers for Patidar Buildcon are: Net Sales at Rs 0.29 crore in September 2024 up 352.93% from Rs. 0.06 crore in September 2023. Quarterly Net Loss at Rs. 0.08 crore in September 2024 down 424.58% from Rs. 0.02 crore in September 2023. EBITDA stands negative at Rs. 0.07 crore in September 2024 down 450% from Rs. 0.02 crore in September 2023.

Reported Standalone quarterly numbers for Vista Pharmaceuticals are: Net Sales at Rs 2.49 crore in September 2024 down 28.1% from Rs. 3.47 crore in September 2023. Quarterly Net Loss at Rs. 0.97 crore in September 2024 up 51.78% from Rs. 2.02 crore in September 2023. EBITDA stands negative at Rs. 0.82 crore in September 2024 up 24.77% from Rs. 1.09 crore in September 2023.